Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income: 2011-2025

Historic Net Income for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Net Income rose 210.07% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 671.57%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Net Income stood at $26.6 million, which was up 212.02% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Net Income ranged from a high of $26.6 million in Q3 2025 and a low of -$24.2 million during Q3 2024.
  • Its 3-year average for Net Income is $4.6 million, with a median of $6.2 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Net Income slumped by 18,372.73% in 2022 and then surged by 1,135.21% in 2024.
  • Ani Pharmaceuticals' Net Income (Quarterly) stood at -$24.1 million in 2021, then spiked by 82.35% to -$4.3 million in 2022, then soared by 127.12% to $1.2 million in 2023, then slumped by 989.70% to -$10.3 million in 2024, then spiked by 210.07% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.